What are the human rights responsibilities of pharmaceutical companies with regard to access to medicines? The state-based international human rights framework has long struggled with the issue of the human rights obligations of non-state actors, a question sharpened by economic globalization and the concomitant growing power of private for-profit actors ("business"). In 2011, after a six-year ...

With respect to special characteristics of pharmaceutical industry and lack of reported performance measure, this study tries to design an integrated PM model for pharmaceutical companies. For generating this model; we first identified the key performance indicators (KPIs) and the key result indicators (KRIs) of a typical pharmaceutical company. Then, based on experts᾽ opinions, the identified ...

BACKGROUND Pharmaceutical companies spent $57.5 billion on pharmaceutical promotion in the United States in 2004. The industry claims that promotion provides scientific and educational information to physicians. While some evidence indicates that promotion may adversely influence prescribing, physicians hold a wide range of views about pharmaceutical promotion. The objective of this review is t...

Manufacturing Process R&D activities are one of the target areas of Irish industrial development agencies in their quest towards embedding pharmaceutical companies in Ireland. This paper analyses the changing role of Ireland in the global process R&D networks of the pharmaceutical companies. The paper is based on data collected in an email survey of all pharmaceutical establishments in Ireland ...

What health professionals know about medicines resembles the information provided in the advertisements of pharmaceutical companies rather than the scientific literature. Drug companies spend 15-20% of their income on promotion. They are responsible for providing adequate information about drugs, and the wording and illustrations should be consistent with the scientific data sheet for the drug ...

The evolution of support for the discovery and development of antibacterial (or antibiotic) agents from the larger pharmaceutical companies to the entrepreneur-like small biotechnology companies has been an experiment in the making for the past 15 years. The word 'experiment' is precisely chosen as the outcome is not certain. Many of the antibiotic biotech organizations that were most likely to...